For research use only. Not for therapeutic Use.
R13 is a prodrug of the selective TrkB agonist 7,8-DHF (Axon 2089) and inhibits AEP and promotes bone formation. TrkB agonist prodrug R13 significantly improved 7,8-DHF oral bioavailability and increased its brain exposure.
KEYWORDS: TrkB agonist prodrug R13 | Supplier | TrkB agonist | R 13 | R-13 | CAS [1609067-49-3] | Neurotrophin | Trk | Activator | Receptors | Tropomyosin-related kinase B receptor | Brain-derived neurotrophic factor | BDNF | Osteoporosis | Alzheimer’s disease
| Catalog Number | I047695 |
| CAS Number | 1609067-49-3 |
| Molecular Formula | C19H16N2O6 |
| Purity | ≥95% |
| IUPAC Name | [8-(methylcarbamoyloxy)-4-oxo-2-phenylchromen-7-yl] N-methylcarbamate |
| InChI | InChI=1S/C19H16N2O6/c1-20-18(23)26-14-9-8-12-13(22)10-15(11-6-4-3-5-7-11)25-16(12)17(14)27-19(24)21-2/h3-10H,1-2H3,(H,20,23)(H,21,24) |
| SMILES | CNC(=O)OC1=C(C2=C(C=C1)C(=O)C=C(O2)C3=CC=CC=C3)OC(=O)NC |
| Reference | C Chen et al. The prodrug of 7,8-dihydroxyflavone development and therapeutic efficacy for treating Alzheimer’s disease. Proc Natl Acad Sci U S A. 2018 Jan 16;115(3):578-583. X Li et al. R13 preserves motor performance in SOD1G93A mice by improving mitochondrial function. Theranostics. 2021 May 24;11(15):7294-7307. J Xiong et al. A TrkB agonist prodrug prevents bone loss via inhibiting asparagine endopeptidase and increasing osteoprotegerin. Nat Commun. 2022 Aug 16;13(1):4820. |
